| Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial SA Wells Jr, BG Robinson, RF Gagel, H Dralle, JA Fagin, M Santoro, ... Journal of clinical oncology 30 (2), 134-141, 2012 | 1717 | 2012 |
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ... Cancer research 62 (24), 7284-7290, 2002 | 734 | 2002 |
| ATM and ATR as therapeutic targets in cancer AM Weber, AJ Ryan Pharmacology & therapeutics 149, 124-138, 2015 | 694 | 2015 |
| Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation SX Pfister, E Markkanen, Y Jiang, S Sarkar, M Woodcock, G Orlando, ... Cancer cell 28 (5), 557-568, 2015 | 321 | 2015 |
| Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers NR Smith, D Baker, NH James, K Ratcliffe, M Jenkins, SE Ashton, ... Clinical Cancer Research 16 (14), 3548-3561, 2010 | 301 | 2010 |
| Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors F Carlomagno, T Guida, S Anaganti, G Vecchio, A Fusco, AJ Ryan, ... Oncogene 23 (36), 6056-6063, 2004 | 295 | 2004 |
| Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option RW William P J Leenders, Benno Küsters, Kiek Verrijp, Cathy Maass, Pieter ... Clin Cancer Research 10 (18), 6222-30, 2004 | 277 | 2004 |
| Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA AJ Ryan, S Squires, HL Strutt, RT Johnson Nucleic acids research 19 (12), 3295-3300, 1991 | 277 | 1991 |
| Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds J Zimmer, EMC Tacconi, C Folio, S Badie, M Porru, K Klare, M Tumiati, ... Molecular cell 61 (3), 449-460, 2016 | 250 | 2016 |
| Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models DC Blakey, FR Westwood, M Walker, GD Hughes, PD Davis, SE Ashton, ... Clinical Cancer Research 8 (6), 1974-1983, 2002 | 250 | 2002 |
| ZD6474–a novel inhibitor of VEGFR and EGFR tyrosine kinase activity AJ Ryan, SR Wedge British journal of cancer 92 (1), S6-S13, 2005 | 222 | 2005 |
| Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells … P Beaudry, J Force, GN Naumov, A Wang, CH Baker, A Ryan, S Soker, ... Clinical Cancer Research 11 (9), 3514-3522, 2005 | 208 | 2005 |
| Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis RS Herbst, JV Heymach, MS O’Reilly, A Onn, AJ Ryan Expert opinion on investigational drugs 16 (2), 239-249, 2007 | 194 | 2007 |
| Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 JL Evelhoch, PM LoRusso, Z He, Z DelProposto, L Polin, TH Corbett, ... Clinical Cancer Research 10 (11), 3650-3657, 2004 | 184 | 2004 |
| ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma M Vidal, S Wells, A Ryan, R Cagan Cancer research 65 (9), 3538-3541, 2005 | 179 | 2005 |
| Vascular endothelial growth factor receptor-1 contributes to resistance to anti–epidermal growth factor receptor drugs in human cancer cells R Bianco, R Rosa, V Damiano, G Daniele, T Gelardi, S Garofalo, V Tarallo, ... Clinical Cancer Research 14 (16), 5069-5080, 2008 | 177 | 2008 |
| ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits … MF McCarty, J Wey, O Stoeltzing, W Liu, F Fan, C Bucana, PF Mansfield, ... Molecular cancer therapeutics 3 (9), 1041-1048, 2004 | 160 | 2004 |
| Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice MV Yezhelyev, G Koehl, M Guba, T Brabletz, KW Jauch, A Ryan, A Barge, ... Clinical Cancer Research 10 (23), 8028-8036, 2004 | 154 | 2004 |
| Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non–small-cell lung cancer EO Hanrahan, HY Lin, ES Kim, S Yan, DZ Du, KS McKee, HT Tran, JJ Lee, ... Journal of Clinical Oncology 28 (2), 193-201, 2010 | 151 | 2010 |
| Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging SP Robinson, DJO McIntyre, D Checkley, JJ Tessier, FA Howe, ... British journal of cancer 88 (10), 1592-1597, 2003 | 136 | 2003 |
Giampaolo TortoraMedical Oncology- Fondazione Policlinico Universitario Gemelli-IRCCS RomaZweryfikowany adres z policlinicogemelli.it